ACC 2019 | Las nuevas guías de prevención primaria ACC/AHA con foco en estilo de vida, dieta y factores socioeconómicos.

ACC 2019 | The New ACC/AHA Guidelines on Primary Prevention Focus on Life Style, Diet and Socioeconomic Factors.

These guidelines basically remind us that we should focus on life style changes to best prevent heart disease, heart failure and atrial fibrillation. These changes, of course, should be permanent. It is estimated that life style changes translate into 80% risk reduction of heart disease.   These recommendations are based on 9 topics: risk estimation,<a href="https://solaci.org/en/2019/03/22/acc-2019-the-new-acc-aha-guidelines-on-primary-prevention-focus-on-life-style-diet-and-socioeconomic-factors/" title="Read more" >...</a>

Los artículos más importantes de 2018 en farmacología / cardiología clínica - 2° parte

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology – Part 2

1- What Antiplatelet Therapy Should We Use in Patients with Stroke/TIA? Interesting Results for the POINT Trial The New England Journal of Medicine (NEJM) recently published an article about the POINT trial (simultaneously presented at the European Stroke Organisation Conference), a long-awaited randomized clinical trial to assess the efficacy and safety of dual antiplatelet therapy<a href="https://solaci.org/en/2019/01/25/the-most-relevant-articles-of-2018-in-pharmacology-and-clinical-cardiology-part-2/" title="Read more" >...</a>

La anticoagulación jugando un papel controvertido en el TAVI

Anticoagulation Plays a Controversial Role in TAVR

Men gender, kidney failure and atrial fibrillation are the factors that most affect 3-year mortality after transcatheter aortic valve replacement. On the other hand, surprisingly enough, anticoagulation (mostly indicated for atrial fibrillation) reduces mortality risk – especially the risk of valve deterioration – after TAVR. Should anticoagulation be included in post TAVR protocols? This question<a href="https://solaci.org/en/2019/01/21/anticoagulation-plays-a-controversial-role-in-tavr/" title="Read more" >...</a>

The Most Relevant Articles of 2018 in Pharmacology and Clinical Cardiology

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more   2- New European Hypertension Guidelines Contrast with American Recommendations The European<a href="https://solaci.org/en/2019/01/21/the-most-relevant-articles-of-2018-in-pharmacology-and-clinical-cardiology/" title="Read more" >...</a>

The 10 most consulted articles at SOLACI during 2018

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more   2- The 10 Commandments of ESC’s New STEMI Guidelines The authors<a href="https://solaci.org/en/2019/01/08/the-10-most-consulted-articles-at-solaci-during-2018/" title="Read more" >...</a>

Can We Discontinue Betablockers after AMI?

Betablockers (BB) were the first drugs shown to effectively reduce events after acute MI. However, reperfusion and other secondary prevention drugs that came along after that have cast a shadow on betablockers’ original benefit. This study looked at betablocker discontinuation after acute MI in patients with no cardiac failure optimally treated with all recommended medication.<a href="https://solaci.org/en/2018/12/10/can-we-discontinue-betablockers-after-ami/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction or coronary angioplasty is quite frequent. According to this study (recently published in JACC), in a real-world population, the combination of direct anticoagulant agents and dual antiplatelet therapy reduces significantly the risk of bleeding and provides similar thromboembolic<a href="https://solaci.org/en/2018/11/20/safety-of-combining-new-anticoagulant-agents-and-dual-antiplatelet-therapy/" title="Read more" >...</a>

ICELAND MI: Unrecognized MI Have Similar Prognosis to Recognized MI

At 10-year follow-up, unrecognized or silent MIs have similar mortality to clinically recognized MI and, even though this does not justify routine screening, these findings call for more aggressive prevention. Unrecognized MI, detected by MRI, is associated to long term mortality risk similar to that of recognized MI; therefore, these patients have higher risk<a href="https://solaci.org/en/2018/10/29/iceland-mi-unrecognized-mi-have-similar-prognosis-to-recognized-mi/" title="Read more" >...</a>

COMPASS: un nuevo lugar para el rivaroxaban en cardiopatía isquémica crónica

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk of all-cause death, thromboembolic events, and bleeding compared with patients who received antiplatelet therapy. The GALILEO trial was halted after an early peek of events at the data from the rivaroxaban (Xarelto; Bayer/Janssen) arm. These events included higher<a href="https://solaci.org/en/2018/10/26/galileo-rivaroxaban-after-tavr-stopped-due-to-early-event-rates/" title="Read more" >...</a>

Los 10 artículos más leídos de septiembre

The 10 most read articles of September

1- High-Sensitivity Troponins Turned All Events into Infarctions; the 4th Universal Definition Clarifies Things Myocardial infarction or myocardial injury? The Fourth Universal Definition of Myocardial Infarction (an update of the 2012 version) is here to clarify that not all cases of elevated cardiac troponin values are acute myocardial infarctions. Read more   2- A Simple<a href="https://solaci.org/en/2018/10/09/the-10-most-read-articles-of-september/" title="Read more" >...</a>

aspirin